Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: A case series
Article first published online: 3 DEC 2010
© 2010 The Authors. Psychiatry and Clinical Neurosciences © 2010 Japanese Society of Psychiatry and Neurology
Psychiatry and Clinical Neurosciences
Volume 65, Issue 1, pages 95–97, February 2011
How to Cite
Chen, C.-Y., Lin, T.-Y., Wang, C.-C. and Shuai, H.-A. (2011), Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: A case series. Psychiatry and Clinical Neurosciences, 65: 95–97. doi: 10.1111/j.1440-1819.2010.02156.x
- Issue published online: 26 JAN 2011
- Article first published online: 3 DEC 2010
- Received 30 November 2009; revised 14 September 2010; accepted 26 September 2010.
- sexual dysfunction
This study examined prolactin levels, sexual function and clinical improvement after switching to aripiprazole from risperidone. Nine schizophrenic male Chinese patients who reported risperidone-induced sexual dysfunction were studied. Clinical Global Impression Scale Scores for Severity (CGI-S), Clinical Global Impression Scale Scores for Improvement (CGI-I), Arizona Sexual Experience Scale results and serum prolactin concentrations were determined over 16 weeks. After treatment with aripiprazole, all patients showed reduced serum prolactin (26.54 ± 17.03 ng/mL to 3.71 ± 1.87 ng/mL, P = 0.008) and five reported improved sexual function. Mean baseline CGI-S (5.11 ± 0.93) decreased to 3.78 ± 1.39 (P = 0.010) by week 16. Compared to baseline (4.0), the mean CGI-I significantly declined by the end of the study (3.44 ± 0.53, P = 0.025).